Navigation Links
Amarantus Announces Upcoming Investor Presentations
Date:5/27/2016

SAN FRANCISCO, May 27, 2016 /PRNewswire/ --

Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced that President & CEO Gerald E. Commissiong will be presenting at two upcoming investor conferences:

SeeThru Equity MicroCap Conference 

Where: Convene Conference Center, 730 Third Avenue, New York City, NY

When: Tuesday, May 31st, 2016 at 3:00pm

Marcum MicroCap Conference 

Where: Grand Hyatt Hotel, 109 East 42nd St, New York, NY

When: Wednesday, June 1st, 2016 at 3:00pm

About Amarantus BioScience Holdings, Inc. 

Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases. AMBS acquired the rights to the Engineered Skin Substitute program (ESS), a regenerative medicine-based approach for treating severe burns with full-thickness autologous skin grown in tissue culture. ESS is entering Phase 2 clinical studies under a CRADA agreement with the US Army. AMBS has development rights to eltoprazine, a Phase 2b-ready small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, adult ADHD and Alzheimer's aggression, and owns the intellectual property rights to a therapeutic protein known as mesencephalic-astrocyte-derived neurotrophic factor (MANF) and is developing MANF-based products as treatments for brain and ophthalmic disorders. AMBS also owns 80 million shares of Avant Diagnostics, Inc. via the sale of its wholly-owned subsidiary Amarantus Diagnostics, Inc. MANF was discovered from the Company's proprietary discovery engine PhenoGuard.

For further information please visit http://www.Amarantus.com, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.

Forward-Looking Statements 

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements. These forward-looking statements generally are identified by the words "believes," "project," "expects," "anticipates," "estimates," "intends," "strategy," "plan," "may," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.

Investor and Media Contact:
Ascendant Partners, LLC
Fred Sommer
+1-732-410-9810
fred@ascendantpartnersllc.com



'/>"/>
SOURCE Amarantus BioScience Holdings, Inc.
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Amarantus Announces Cancellation of Special Meeting of Shareholders
2. Amarantus Appoints Brian E. Harvey, MD PhD to Strategic Advisory Board
3. Amarantus to Present at Source Capital Groups 2016 Disruptive Growth & Healthcare Conference
4. Amarantus Receives Dual Notices of Allowance from European Patent Office for Engineered Skin Substitute (ESS)
5. Amarantus Enters Into Letter of Intent to Merge Diagnostics Business Unit Into Avant Diagnostics
6. Amarantus to Present at ICV Sonoma Event
7. Amarantus to Present at SeeThruEquity First Annual Microcap Healthcare Investor Conference
8. Amarantus Requests Rare Pediatric Disease and Orphan Drug Designations from US FDA for Engineered Skin Substitute in the Treatment of Giant Congenital Melanocytic Nevi
9. Amarantus Provides Update on cGMP Manufacturing Validation for the Engineered Skin Substitute (ESS) Program
10. Amarantus Receives Notice of Allowance for U.S. Patent Application Covering Method of Treating Parkinsons Disease Levodopa-induced Dyskinesia (PD-LID)
11. NxStage Announces Second Quarter 2016 Investor Conference Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2019)... BALTIMORE (PRWEB) , ... August 17, 2019 , ... The ... the Veterans Affairs (VA) Maryland Health Care System for the benefit of veteran patients, ... system just one month ago. , This most recent donation from Post ...
(Date:8/16/2019)... ... August 16, 2019 , ... A new medical device for ... that both corrects the curve and maintains flexibility in the spine. , The ... by medical staff of Shriners Hospitals for Children® — Philadelphia. It is the ...
(Date:8/16/2019)... ... 2019 , ... SignatureCare Emergency Center has announced that it ... Montrose, Heights, Memorial City, and Bellaire, TX. , The one-day health fair on ... at helping Houston families get their children caught up on wellness checks, immunizations ...
Breaking Medicine Technology:
(Date:8/16/2019)... ... August 16, 2019 , ... Cannabinoid Biosciences (“CBDZ”), the Los ... products across the CBD market in the United States in particular and to ... $50 million on September 9, 2019. , Established on May 6, 2014, Cannabinoid ...
(Date:8/15/2019)... ... August 15, 2019 , ... ... its annual Inc. 5000 list, the most prestigious ranking of the nation’s fastest-growing ... within the American economy’s most dynamic segment—its independent small businesses. Microsoft, Dell, Domino’s ...
(Date:8/14/2019)... , ... August 14, 2019 , ... Teguar Corporation has ... in America. This list has long-been established as a mark of success for some ... Dell, and Oracle. Teguar made the list in 2015, 2016 and 2017. This year, ...
(Date:8/14/2019)... , ... August 13, 2019 , ... ... joined the esteemed Haute Beauty network. , The Haute Beauty Network, well known ... Dr. Reyes-Bergano as a leading aesthetic medicine expert and our newest addition to ...
(Date:8/12/2019)... ... August 12, 2019 , ... Eco Pump Services is an ... Florida 33027. For over 25 years, Eco Pump Services has served customers with excellence ... pumping services . Eco Pump’s steady five-star ratings and excellent customer reactions throughout numerous ...
Breaking Medicine News(10 mins):